Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease

With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentys.